Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Cyclerion Therapeutics Inc

CYCN
Current price
2.49 USD +0.31 USD (+14.06%)
Last closed 2.18 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 6 079 985 USD
Yield for 12 month +203.32 %
Week
Month
Year
CYCN
21.11.2021 - 28.11.2021

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is Zagociguat (CY6463), a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018, a CNS-targeted sGC stimulator that is in preclinical trial for the treatment of neuropsychiatric diseases and disorders. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. Address: 245 First Street, Cambridge, MA, United States, 02142

Analytics

WallStreet Target Price

4 USD

P/E ratio

Dividend Yield

Current Year

+297 000 USD

Last Year

+3 320 000 USD

Current Quarter

Last Quarter

Current Year

+297 000 USD

Last Year

+3 320 000 USD

Current Quarter

Last Quarter

Key Figures CYCN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -38 090 248 USD
Operating Margin TTM -2871.91 %
PE Ratio
Return On Assets TTM -118.39 %
PEG Ratio
Return On Equity TTM -279.31 %
Wall Street Target Price 4 USD
Revenue TTM 1 328 000 USD
Book Value 5.27 USD
Revenue Per Share TTM 0.59 USD
Dividend Share
Quarterly Revenue Growth YOY 14.1 %
Dividend Yield
Gross Profit TTM -29 749 000 USD
Earnings Share -18.53 USD
Diluted Eps TTM -18.53 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CYCN

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CYCN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:20
Payout Ratio
Last Split Date 16.05.2023
Dividend Date

Stock Valuation CYCN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 0.517
Price Sales TTM 4.5783
Enterprise Value EBITDA 1.2554
Price Book MRQ 0.4723

Financials CYCN

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators CYCN

For 52 weeks

1.75 USD 19.14 USD
50 Day MA 2.82 USD
Shares Short Prior Month 15 482
200 Day MA 5.15 USD
Short Ratio 4.04
Shares Short 13 306
Short Percent 0.77 %